warfarin orion 3 mg
orion corporation, fínsko - warfarín - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
warfarin orion 5 mg
orion corporation, fínsko - warfarín - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
hotemin 20 mg
egis pharmaceuticals plc - piroxikam - 29 - antirheumatica, antiphlogistica, antiuratica
dexa-ratiopharm 4
ratiopharm gmbh - dexametazón - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
flamexin 20 mg
chiesi farmaceutici s.p.a., taliansko - piroxikam - 29 - antirheumatica, antiphlogistica, antiuratica
warfarin pmcs 5 mg
pro.med.cs praha a.s., Česká republika - warfarín - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
warfarin pmcs 2 mg
pro.med.cs praha a.s., Česká republika - warfarín - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
erlotinib mylan 150 mg
mylan ireland limited, Írsko - erlotinib - 44 - cytostatica
erlotinib mylan 100 mg
mylan ireland limited, Írsko - erlotinib - 44 - cytostatica
azacitidine celgene
celgene europe bv - azacitidín - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastické činidlá - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.